Enanta Pharma (ENTA) Tops Q4 EPS by 11c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
November 26, 2018 4:01 PM ESTWebcast and Conference Call today at 4:30 p.m. ET
Royalty revenue for the quarter increased to $67.2 million Net income was $27.4 million, or $1.30 per diluted common share Cash and marketable securities totaled $325.1 million Phase 2a study initiated with EDP-938 against respiratory syncytial virus (RSV) infection in a human challenge study Hepatitis B virus (HBV) candidate EDP-514 selected for clinical development in 2019WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc.... More
